UBS Maintains Buy on Veracyte, Lowers Price Target to $35
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $65 to $35.
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $65 to $35.